AstraZeneca Forxiga meets primary endpoint for type 2 diabetes Ruchika Sharma8 Oct 2023 10:00 AM ISTCambridge: AstraZeneca has announced positive results from the T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed...
AstraZeneca Forxiga approved in China to reduce cardiovascular death, hospitalisation risk in adults with symptomatic chronic heart failure Ruchika Sharma20 Aug 2023 1:30 PM ISTForxiga is a first-in-class, oral, once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2).
AstraZeneca Forxiga approved in EU for treatment of symptomatic chronic heart failure Ruchika Sharma7 Feb 2023 4:15 PM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
AstraZeneca Forxiga recommended for nod in EU for chronic heart failure Ruchika Sharma20 Dec 2022 5:30 PM ISTHeart failue is a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affecting 15 million people in the EU.
CDSCO nod to AstraZeneca Pharma Dapagliflozin tablets Ruchika Sharma28 Nov 2022 4:30 PM ISTThe receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded...
AstraZeneca Forxiga gets Chinese nod to treat CKD with and without type 2 diabetes Ruchika Sharma6 Sept 2022 11:15 AM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
AstraZeneca gets nod for CKD, type 2 diabetes treatment Forxiga in Japan Ruchika Sharma29 Aug 2021 10:15 AM ISTUK: AstraZeneca has recently announced that Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in...
Abbott, AstraZeneca terminate agreement for diabetes drug Dapagliflozin in India Ruchika Sharma30 May 2021 10:15 AM ISTNew Delhi: Drug major AstraZeneca Pharma India on Friday said it has terminated its distribution agreements with Abbott Healthcare for type 2 diabetes...
AstraZeneca gets CDSCO nod for Dapagliflozin in CKD MD Bureau17 Jan 2021 3:30 PM ISTNew Delhi: The Subject Expert Committee (SEC), operative under the Central Drugs Standard Control Organization (CDSCO), has given its nod to...
Dapagliflozin going off-patent- NPPA brings Dapagliflozin, Metformin Combination under price control Farhat Nasim14 Jan 2021 5:15 PM ISTNew Delhi: With the popular antidiabetic drug, Dapagliflozin going off-patent, the apex drug price regulator, National Pharmaceutical Pricing...
Dapagliflozin NOT off Patent, says AstraZeneca Medical Dialogues Bureau23 Nov 2020 3:14 PM ISTNew Delhi: The arrival of SGLT-2 inhibitors or Glifozins, has brought a major change in the management of Diabetes in the past decade. Numerous pharma...
Price war over Diabetes drug Dapagliflozin: AstraZeneca drags 12 drugmakers to Delhi court Farhat Nasim16 Oct 2020 5:30 PM ISTNew Delhi: Proclaiming a legal battle against 12 Indian drugmakers, AstraZeneca has moved Delhi high court against the dozen firms for eyeing to roll...
